+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Multicenter susceptibility testing of Candida clinical isolates to caspofungin by three different methods

Multicenter susceptibility testing of Candida clinical isolates to caspofungin by three different methods

Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 406

Objective: To study the agreement between M27-A, M27-A+2% glucose (M27-A+g) and Sensititre Yeast One(R) (SYO) methods for yeast susceptibility testing to caspofungin. Methods: 25 blood culture Candida isolates (9 C. albicans, 5 C. parapsilosis, 3 C. krusei, 3 C. glabrata, 2 C. tropicalis, and 2 C. guilliermondii) were simultaneously tested in 5 centers using the same batches of reagents. ATCC 90028, ATCC 6258, and 6 genetically modified caspofungin-resistant Candida strains were used as controls. SYO plates had added caspofungin at concentrations ranging from 0.016 to 16 mg/L. Readings were performed at 24 and 48 h for SYO, 24 h for M27-A+g, and 48 h for M27-A. MIC was the concentration that inhibited 100% of control growth. Results: The overall interlaboratory agreements (+-2 log dilutions) were: M27-A vs SYO 24 h, 79.4% (range, 75-88.9); M27-A vs SYO 48 h, 87.1% (range, 75-97.2); and M27-A vs M27-A+g, 92.1% (range, 69.7-100). Intralaboratory agreements among methods were higher. Both M27-A+g and SYO methods yielded MIC values for the genetically modified caspofungin-resistant strains in agreement with previous reports (Douglas et al. 1997. AAC 41: 2471). Conclusions: The colorimetric method SYO is a fine, reproducible method to test susceptibility of Candida to caspofungin, showing optimal correlation with NCCLS M27-A when MIC readings were performed at 48 h. Both M27-A+g and SYO detected properly caspofungin-susceptible strains of Candida spp. Thus, SYO could be an alternative method in clinical laboratories for testing Candida susceptibility to caspofungin. Yet, its applicability to the detection of clinically relevant caspofungin-resistant strains remains to be determined.

(PDF emailed within 1 workday: $29.90)

Accession: 035349956

Download citation: RISBibTeXText

Related references

Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study. Antimicrobial Agents and ChemoTherapy 49(4): 1604-1607, 2005

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrobial Agents and ChemoTherapy 48(4): 1382-1383, 2004

Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrobial Agents and ChemoTherapy 56(7): 3965-3968, 2012

Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. Journal of Clinical Microbiology 42(7): 3117-3119, 2004

Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria. Journal of Clinical Microbiology 52(9): 3223-3229, 2015

Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. Journal of Clinical Microbiology 52(1): 108-114, 2014

Multicenter Comparison of the Etest and EUCAST Methods for Antifungal Susceptibility Testing of Candida Isolates to Micafungin. Antimicrobial Agents and ChemoTherapy 60(8): 5088-5091, 2017

Comparative in vitro susceptibility of clinical isolates of Candida paparsilosis complex and other Candida species to caspofungin and anidulafungin by Etest. Journal of ChemoTherapy 23(2): 97-101, 2012

Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates. Brazilian Journal of Microbiology 40(1): 163-169, 2009

Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. Journal of Antimicrobial ChemoTherapy 62(5): 1094-1100, 2008

In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrobial Agents and ChemoTherapy 50(11): 3926-3928, 2006

Fluconazole susceptibility testing of Candida inconspicua clinical isolates: comparison of four methods. Journal of Antimicrobial ChemoTherapy 55(2): 275-276, 2005

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrobial Agents and ChemoTherapy 45(1): 327-330, 2000

Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration. Antimicrobial Agents and ChemoTherapy 49(8): 3486-3488, 2005

Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. Journal of Clinical Microbiology 49(5): 1765-1771, 2011